Pharmacological inhibition of HDAC6 using agents such as MPT0B291 has been shown to downregulate the expression of DNA damage response genes, induce DNA damage, and impair homologous recombination repair in GBM cells, including those resistant to temozolomide. Here, HDAC6 is linked to glioblastoma.